New approaches to the delivery of drugs to the brain.
The Human Immunodeficiency Virus (HIV) is the causative agent of AIDS and this has been found to be neurotropic. For this reason the development of an effective strategy for the delivery of antiviral drugs across the blood-brain barrier is of paramount importance in the treatment of HIV infection. There are insulin receptors on the capillary endothelial cells making up the blood-brain barrier (BBB) and it is proposed that these may play a role, along with exogenously administered insulin, in enhancing the transport of drug molecules across the BBB. Evidence is presented showing that insulin may be used as a pharmacologic adjunct in the therapy of HIV infection by allowing for higher concentrations of antiviral drugs to be obtained within the CNS using lower total doses of drug. This would enhance the drug's therapeutic effectiveness while simultaneously obviating potential dose-related side-effects.
Ayre
S G
SG
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000277:Adjuvants, Pharmaceutic; D001693:Biological Transport, Active; D001812:Blood-Brain Barrier; D001921:Brain / Q000502:physiology; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D011972:Receptor, Insulin / Q000502:physiology; D015215:Zidovudine / Q000627:therapeutic use
D000277:Adjuvants, Pharmaceutic; D007328:Insulin; D015215:Zidovudine; D011972:Receptor, Insulin